Specifically, trastuzumab and pertuzumab, humanized monoclonal antibodies that bind to different domains of the HER2 receptor, have demonstrated efficacy in clinical trials and are currently approved for use in combination with chemotherapy as the standard of care for HER2-positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.